Business
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (\"Oncolytics\" or the \"Company\"), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed a registration statement on Form F-4 with the Securities and Exchange Commission (the \"SEC\") that includes a preliminary management circular/prospectus and other relevant documents related to various proposals contained therein, and has plans to hold a Special Meeting of Shareholders (the \"Special Meeting\") to vote on, among other things, a series of transactions that will change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States of America (the \"Domestication\"). In order to facilitate the Domestication, the Company expects to, prior to the Domestication, continue its existence from the Province of Alberta to the Province of British Columbia (the \"Continuance\"). The Continuance and the Domestication require approval by the affirmative vote of not less than two-thirds of the votes cast at the Special Meeting by proxy or in person. If approved, the Domestication is expected to occur on January 1, 2026, or as soon as practicable thereafter. There are not expected to be any material changes to the Company's operations or financial results as a result of the Continuance or Domestication. The Company will continue to be subject to SEC reporting requirements and, as applicable, Canadian securities laws, and its common equity securities will continue to trade on the Nasdaq Capital Market under the symbol \"ONCY.\"\n \n \n \n \n \n \n \n The Domestication is intended to reduce the regulatory burden and cost of being subject to the laws and regulations of both the United States and Canada and to facilitate stockholder value creation over the long term by, among other things, reducing our operating costs and enabling us to compete effectively in raising the capital necessary for us to continue to implement our strategic plan. In addition, most of the Company's operations are located in the United States, and a large percentage of our shareholders are located in the United States. We chose the State of Nevada to be our domicile because of its favorable corporate environment and because the NRS expressly accommodates a continuance authorized by the Business Corpor...